Fundraising Fox
Neuron23
South San Francisco, US · Founded 2018 · 29 employees on LinkedIn · 12 known investors
Find your way into Neuron23
Sign up to find every way you can get introduced to Neuron23
- Your email: who you already know at Neuron23, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Neuron23 team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Neuron23 is a biotech company using data science, human genetics, and functional genomics to develop precision medicines and companion diagnostics for neurodegenerative diseases, starting with an LRRK2 program for Parkinson's disease. It aims to match patient subsets defined by genetic drivers with targeted therapies for conditions such as Parkinson's and Alzheimer's.
Founders & leadership
Investors · 12
How we know: HBM Healthcare Investments's portfolio page · Not right? Tell us
How we know: HBM Partners's portfolio page · worldpharmaceuticals.net · Not right? Tell us
How we know: Kleiner Perkins's portfolio page · a partner's Signal profile · worldpharmaceuticals.net · Not right? Tell us
How we know: SoftBank Group's portfolio page · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: Westlake Village BioPartners's portfolio page · funding news · worldpharmaceuticals.net · Not right? Tell us
Also in the syndicate · 3
Funding
SEC filings, press & company announcements- Undisclosed amountSeries DJun 2025 · 2 sourcesSource ↗
- Undisclosed amountSeries CMar 2022 · 2 sources
SoftBank Vision Fund 2 (lead), Acorn Bioventures, Cowen Healthcare Investments, HBM Partners, Kleiner Perkins, Perceptive Advisors, Redmile Group, Surveyor Capital, Westlake Village BioPartners
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Neuron23 do?
- Neuron23 is a biotech company using data science, human genetics, and functional genomics to develop precision medicines and companion diagnostics for neurodegenerative diseases, starting with an LRRK2 program for Parkinson's disease. It aims to match patient subsets defined by genetic drivers with targeted therapies for conditions such as Parkinson's and Alzheimer's.
- Who are Neuron23's investors?
- Neuron23's investors include HBM Healthcare Investments, HBM Partners, Kleiner Perkins, SoftBank Group, SoftBank Vision Fund, Westlake Village BioPartners, ACORN BIOVENTURES, Cowen Healthcare Investments and 1 more.
- Where is Neuron23 headquartered?
- Neuron23 is headquartered in South San Francisco, US.